These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38922648)

  • 1. Effectiveness, Safety, and Acceptability of Primaquine Mass Drug Administration in Low-Endemicity Areas in Southern Thailand: Proof-of-Concept Study.
    Kaewkungwal J; Roobsoong W; Lawpoolsri S; Nguitragool W; Thammapalo S; Prikchoo P; Khamsiriwatchara A; Pawarana R; Jarujareet P; Parker DM; Sripoorote P; Kengganpanich M; Ngamjarus C; Sattabongkot J; Cui L
    JMIR Public Health Surveill; 2024 Jun; 10():e51993. PubMed ID: 38922648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.
    Aung PL; Soe MT; Soe TN; Oo TL; Aung PP; Khin A; Thi A; Phuanukoonnon S; Okanurak K; Cui L; Kyaw MP; Parker DM
    Parasit Vectors; 2021 Oct; 14(1):549. PubMed ID: 34689796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.
    Saita S; Roobsoong W; Khammaneechan P; Sukchan P; Lawpoolsri S; Sattabongkot J; Cui L; Okanurak K; Phuanukoonnon S; Parker DM
    Malar J; 2023 Jan; 22(1):17. PubMed ID: 36635642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
    Milligan R; Daher A; Graves PM
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012656. PubMed ID: 31274189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
    Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.
    Phommasone K; van Leth F; Imwong M; Henriques G; Pongvongsa T; Adhikari B; Peto TJ; Promnarate C; Dhorda M; Sirithiranont P; Mukaka M; Peerawaranun P; Day NPJ; Cobelens F; Dondorp AM; Newton PN; White NJ; von Seidlein L; Mayxay M
    Malar J; 2020 Jan; 19(1):4. PubMed ID: 31900172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.
    Takeuchi R; Lawpoolsri S; Imwong M; Kobayashi J; Kaewkungwal J; Pukrittayakamee S; Puangsa-art S; Thanyavanich N; Maneeboonyang W; Day NP; Singhasivanon P
    Malar J; 2010 Nov; 9():308. PubMed ID: 21040545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
    Taylor WRJ; Thriemer K; von Seidlein L; Yuentrakul P; Assawariyathipat T; Assefa A; Auburn S; Chand K; Chau NH; Cheah PY; Dong LT; Dhorda M; Degaga TS; Devine A; Ekawati LL; Fahmi F; Hailu A; Hasanzai MA; Hien TT; Khu H; Ley B; Lubell Y; Marfurt J; Mohammad H; Moore KA; Naddim MN; Pasaribu AP; Pasaribu S; Promnarate C; Rahim AG; Sirithiranont P; Solomon H; Sudoyo H; Sutanto I; Thanh NV; Tuyet-Trinh NT; Waithira N; Woyessa A; Yamin FY; Dondorp A; Simpson JA; Baird JK; White NJ; Day NP; Price RN
    Lancet; 2019 Sep; 394(10202):929-938. PubMed ID: 31327563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
    Phommasone K; van Leth F; Peto TJ; Landier J; Nguyen TN; Tripura R; Pongvongsa T; Lwin KM; Kajeechiwa L; Thwin MM; Parker DM; Wiladphaingern J; Nosten S; Proux S; Nguon C; Davoeung C; Rekol H; Adhikari B; Promnarate C; Chotivanich K; Hanboonkunupakarn B; Jittmala P; Cheah PY; Dhorda M; Imwong M; Mukaka M; Peerawaranun P; Pukrittayakamee S; Newton PN; Thwaites GE; Day NPJ; Mayxay M; Hien TT; Nosten FH; Cobelens F; Dondorp AM; White NJ; von Seidlein L
    PLoS One; 2020; 15(2):e0228190. PubMed ID: 32023293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial.
    von Seidlein L; Peto TJ; Landier J; Nguyen TN; Tripura R; Phommasone K; Pongvongsa T; Lwin KM; Keereecharoen L; Kajeechiwa L; Thwin MM; Parker DM; Wiladphaingern J; Nosten S; Proux S; Corbel V; Tuong-Vy N; Phuc-Nhi TL; Son DH; Huong-Thu PN; Tuyen NTK; Tien NT; Dong LT; Hue DV; Quang HH; Nguon C; Davoeung C; Rekol H; Adhikari B; Henriques G; Phongmany P; Suangkanarat P; Jeeyapant A; Vihokhern B; van der Pluijm RW; Lubell Y; White LJ; Aguas R; Promnarate C; Sirithiranont P; Malleret B; Rénia L; Onsjö C; Chan XH; Chalk J; Miotto O; Patumrat K; Chotivanich K; Hanboonkunupakarn B; Jittmala P; Kaehler N; Cheah PY; Pell C; Dhorda M; Imwong M; Snounou G; Mukaka M; Peerawaranun P; Lee SJ; Simpson JA; Pukrittayakamee S; Singhasivanon P; Grobusch MP; Cobelens F; Smithuis F; Newton PN; Thwaites GE; Day NPJ; Mayxay M; Hien TT; Nosten FH; Dondorp AM; White NJ
    PLoS Med; 2019 Feb; 16(2):e1002745. PubMed ID: 30768615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
    Gogtay N; Kannan S; Thatte UM; Olliaro PL; Sinclair D
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD008492. PubMed ID: 24163021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia.
    Gebrie H; Yimer M; Ayehu A; Mohammed H; Hailgiorgis H; Wuletaw Y; Hailu M; Tolera G; Tasew G; Kassa M; Gidey B
    Malar J; 2024 Jul; 23(1):202. PubMed ID: 38971786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    Douglas NM; Poespoprodjo JR; Patriani D; Malloy MJ; Kenangalem E; Sugiarto P; Simpson JA; Soenarto Y; Anstey NM; Price RN
    PLoS Med; 2017 Aug; 14(8):e1002379. PubMed ID: 28850568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass drug administration for malaria.
    Poirot E; Skarbinski J; Sinclair D; Kachur SP; Slutsker L; Hwang J
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008846. PubMed ID: 24318836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Chu CS; Phyo AP; Turner C; Win HH; Poe NP; Yotyingaphiram W; Thinraow S; Wilairisak P; Raksapraidee R; Carrara VI; Paw MK; Wiladphaingern J; Proux S; Bancone G; Sriprawat K; Lee SJ; Jeeyapant A; Watson J; Tarning J; Imwong M; Nosten F; White NJ
    Clin Infect Dis; 2019 Apr; 68(8):1311-1319. PubMed ID: 30952158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
    Landier J; Parker DM; Thu AM; Lwin KM; Delmas G; Nosten FH;
    Lancet; 2018 May; 391(10133):1916-1926. PubMed ID: 29703425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.
    McLean ARD; Indrasuta C; Khant ZS; Phyo AK; Maung SM; Heaton J; Aung H; Aung Y; Soe K; Swe MMM; von Seidlein L; Tun NN; Tun KM; Day NPJ; Ashley EA; Hlaing T; Kyaw TT; Dondorp AM; Imwong M; White NJ; Smithuis FM
    Lancet Infect Dis; 2021 Nov; 21(11):1579-1589. PubMed ID: 34147154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.
    Silachamroon U; Krudsood S; Treeprasertsuk S; Wilairatana P; Chalearmrult K; Mint HY; Maneekan P; White NJ; Gourdeuk VR; Brittenham GM; Looareesuwan S
    Am J Trop Med Hyg; 2003 Jul; 69(1):14-8. PubMed ID: 12932090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study.
    Nekkab N; Lana R; Lacerda M; Obadia T; Siqueira A; Monteiro W; Villela D; Mueller I; White M
    PLoS Med; 2021 Apr; 18(4):e1003535. PubMed ID: 33891582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.